BB Biotech AGBION:SWX

312.75
10.75 / 3.56%
12.43k
74.62%
0.9689
Latest price in CHFToday's changeShares traded1 year changeBeta
Data delayed at least 30 minutes, as of Mar 06 2015 08:44 GMT.

Summary

BB Biotech AG (BION:SWX) set a new 52-week high during today's trading session when it reached 314.75. Over this period, the share price is up 81.51%.

52-week range
Today
132.10
Apr 14 2014
314.75
Mar 06 2015
Markit short selling activity
Low
Medium
High
Open307.00
Day high314.75
Day low307.00
Bid312.50
Offer313.25
Previous close302.00
Average volume49.37k
Shares outstanding11.85m
Free float10.63m
P/E (TTM)2.32
Market cap3.58bn CHF
EPS (TTM)130.03 CHF
Annual div (IAD)11.60 CHF
Annual div yield (IAD)4.03%
Div ex-dateMar 21 2014
Div pay-dateMar 26 2014
Next div ex-dateMar 20 2015
Next div pay-dateMar 24 2015
Data delayed at least 30 minutes, as of Mar 06 2015 08:44 GMT.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
BB Biotech AG+9.74 %+23.74 %+79.54 %+74.62 %+317.84 %
ALL SHARE CH X INDEX+0.73 %+6.11 %+3.52 %+7.25 %+31.31 %
Data delayed at least 30 minutes, as of Mar 06 2015 08:44 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.